Connect
← Return to Issues with ProACT incontinence value
Discussion
Issues with ProACT incontinence value
Prostate Cancer | Last Active: Sep 21 11:34am | Replies (27)Comment receiving replies
Read the article and got the impression that this drug is NOT a radio pharmaceutical drug like Pluvicto. Is that correct?
Updated: I read the following about this drug - ARV-766, also known as luxdegalutamide, is an investigational oral drug developed by Arvinas for the treatment of metastatic castration-resistant prostate cancer (mCRPC). It belongs to a class of drugs called proteolysis-targeting chimeras (PROTACs), which are designed to selectively degrade specific proteins within cells.
Replies to "Read the article and got the impression that this drug is NOT a radio pharmaceutical drug..."
Connect
You know as much about it as I do. There was a precursor to this drug that never got anywhere, but was quite promising (Protac ARV-110), PROTAC ARV-766 advanced the development further.
I guess AI is about the only place you can find more information about this. Do searches on the web about that drug name and you will see most of the information that is available.